Abstract:Purpose To study the immunotherapeutic effects and its mechanism of BCG-Polysaccharide Nucleic Acid (BCG-PSN) on murine infection with mycobacterium tuberculosis. Methods Forty-eight BALB/c mice were randomized into 2 groups,A group treated with BCG-PSN,B group treated with saline (n=24). 1×106 bacili in a volume of 300 μL saline were injected into the tail vein of mice in A and B groups.The mice from both group were treated with BCG-PSN (10 mg/kg once a day for 7 days)and saline (10 mL/kg once a day for 7 days) intraperitoneally respectively 1 week postinfection.The animals were sacrificed at 3 weeks and 4 weeks postinfection respectively.The weight of body,lung and spleen were measured.Then the lung and spleen of mice were fixed in 10% buffered formalin,paraffin embedded,and processed for histological examination. The numbers of viable bacteria in lung and spleen were counted. The expression of IFN-γ mRNA,IL-10 mRNA and IL-4 mRNA in lung and spleens were detected by real-time PCR method. Results At 4 weeks postinfection,the body weight of mice in A group was higher than that in B group,the lung weight of mice in A group was lower than that in B group,the spleen weight of mice in A group was higher than that in B group. At 3 weeks and 4 weeks postinfection,the numbers of viable bacteria in lungs and spleens of mice from A group were lower than that in B group respectively.At 3 weeks and 4 weeks postinfection,the expression of IFN-γ mRNA in lung tissue of mice from A group was similar to that in B group,the expression of IL-10 mRNA and IL-4 mRNA were less than those in B group respectively. At 3 weeks postinfection,the expression of IFN-γ mRNA in spleen tissue of mice from A group was similar to that in B group,while at 4 weeks postinfection,the expression of IFN-γ mRNA in spleen tissue of mice from A group was more than that in B group. At 3 weeks and 4 weeks postinfection,the expression of IL-10 mRNA and IL-4 mRNA were less than those in B group respectively. Conclusions BCG-PSN could improve host defence against mycobacterium tuberculosis and reduce mycobacterial outgrowth during tuberculosis and were associated with a decrease in inflammation in lung tissue by activating the Th1 response.

Evaluation synergism of GLS/IL-12 recombinant BCG to anti-tuberculosis chemotherapy in murine model of M.tuberculosis infection

The Diagnostic Efficiency Evaluation of Combination Tuberculosis Interferon-Gamma Release Assay with Human Leukocyte Antigen-G for Tuberculosis

Immunotherapeutic Effects of BCG-Polysaccharide Nucleic Acid on Murine with Pulmnary Tuberculosis

Recombinant Bacille Calmette-Guérin coexpressing Ag85B-IFN-γ enhances the cell-mediated immunity in C57BL/6 mice.

Enhanced Protective Efficacy Against Mycobacterium Tuberculosis Afforded by BCG Prime‐dna Boost Regimen in an Early Challenge Mouse Model is Associated with Increased Splenic Interleukin‐2‐producing CD4 T‐cell Frequency Post‐vaccination

Immune Correlates of Disseminated BCG Infection in IL12RB1-Deficient Mice

Early introduction of IL-10 weakens BCG revaccination's protection by suppressing CD4+Th1 cell responses

Evaluation Of A New Recombinant Bcg Which Contains Mycobacterial Antigen Ag85b-Mpt64(190-198)-Mtb8.4 In C57/Bl6 Mice

Effects of Bacillus Calmette Guerin-Polysaccharide nucleic acid on expression of interferon-gamma, tumor necrosis factor-alpha and interleukin-10 mRNA in peripheral blood mononuclear cells from patients with pulmonary tuberculosis

Novel recombinant BCG coexpressing Ag85B, ESAT-6 and mouse TNF-α induces significantly enhanced cellular immune and antibody responses in C57BL/6 mice: Recombinant BCG expressing Ag85B-ESAT-6-TNF-α

Enhanced Immune Responses Against Mycobacterium tuberculosis Through Heat-Killed BCG with Squalene-in-water Emulsion Adjuvant

Heterologous Boosting With Listeria -Based Recombinant Strains in BCG-Primed Mice Improved Protection Against Pulmonary Mycobacterial Infection.

Immunotherapy Using IL-2 and GM-CSF is a Potential Treatment for Multidrug-Resistant Mycobacterium Tuberculosis

Heterologous Boosting With<i>Listeria</i>-Based Recombinant Strains in BCG-Primed Mice Improved Protection Against Pulmonary Mycobacterial Infection

A practical approach for excess bandwidth distribution for EPONs

Recombinant Bcg Coexpressing Ag85b, Esat-6 and Mouse-Ifn-Gamma Confers Effective Protection Against Mycobacterium Tuberculosis in C57bl/6 Mice

More vaccine efficacy studies on the recombinant bacille calmette-guerin co-expressing Ag85B, Mpt64 190-198 and Mtb8.4

A novel recombinant BCG-expressing pro-apoptotic protein BAX enhances Th1 protective immune responses in mice.

Recombinant BCG vaccine expressing multistage antigens of Mycobacterium tuberculosis provides long-term immunity against tuberculosis in BALB/c mice

More vaccine efficacy studies on the recombinant Bacille Calmette-Guerin co-expressing Ag85B, Mpt64 and Mtb8.4.

Immunogenic profiling of Mycobacterium tuberculosis Rv1513 reveals its ability to switch on Th1 based immunity